USP24-i-101 targeting of USP24 activates autophagy to inhibit drug resistance acquired during cancer therapy

Drug resistance in Cancer therapy is the major reason for poor prognosis. Addressing this clinically unmet issue is important and urgent. In this study, we found that targeting USP24 by the specific USP24 inhibitors, USP24-i and its analogues, dramatically activated Autophagy in the interphase and mitotic periods of lung Cancer cells by inhibiting E2F4 and TRAF6, respectively. USP24 functional knockout, USP24^C1695A, or targeting USP24 by USP24-i-101 inhibited drug resistance and activated Autophagy in gefitinib-induced drug-resistant mice with doxycycline-induced EGFR^L858R lung Cancer, but this effect was abolished after inhibition of Autophagy, indicating that targeting USP24-mediated induction of Autophagy is required for inhibition of drug resistance. Genomic instability and PD-L1 levels were increased in drug resistant lung Cancer cells and were inhibited by USP24-i-101 treatment or knockdown of USP24. In addition, inhibition of Autophagy by bafilomycin-A1 significantly abolished the effect of USP24-i-101 on maintaining genomic integrity, decreasing PD-L1 and inhibiting drug resistance acquired in chemotherapy or targeted therapy. In summary, an increase in the expression of USP24 in Cancer cells is beneficial for the induction of drug resistance and targeting USP24 by USP24-i-101 optimized from USP24-i inhibits drug resistance acquired during Cancer therapy by increasing PD-L1 protein degradation and genomic stability in an Autophagy induction-dependent manner.